These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25666939)

  • 1. Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ.
    Tamura N; Tsuda H; Yoshida M; Hojo T; Akashi-Tanaka S; Kinoshita T; Sugihara K
    Breast Cancer; 2016 May; 23(3):510-8. PubMed ID: 25666939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
    Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
    JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study.
    Li Q; Wang K; Yang L; Wu Q; Zhu W; Li Z; Shi Y; Zhang X; Li H
    Clin Breast Cancer; 2021 Aug; 21(4):360-372. PubMed ID: 33846099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
    Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
    Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
    Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of clinical and pathologic features with outcome in patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery and radiotherapy.
    Rodrigues N; Carter D; Dillon D; Parisot N; Choi DH; Haffty BG
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1331-5. PubMed ID: 12459354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.
    Fisher ER; Costantino J; Fisher B; Palekar AS; Paik SM; Suarez CM; Wolmark N
    Cancer; 1996 Oct; 78(7):1403-16. PubMed ID: 8839545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?
    Miller ME; Muhsen S; Olcese C; Patil S; Morrow M; Van Zee KJ
    Ann Surg Oncol; 2017 Oct; 24(10):2889-2897. PubMed ID: 28766208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Background parenchymal signal enhancement ratio at preoperative MR imaging: association with subsequent local recurrence in patients with ductal carcinoma in situ after breast conservation surgery.
    Kim SA; Cho N; Ryu EB; Seo M; Bae MS; Chang JM; Moon WK
    Radiology; 2014 Mar; 270(3):699-707. PubMed ID: 24126372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision.
    Yi M; Meric-Bernstam F; Kuerer HM; Mittendorf EA; Bedrosian I; Lucci A; Hwang RF; Crow JR; Luo S; Hunt KK
    J Clin Oncol; 2012 Feb; 30(6):600-7. PubMed ID: 22253459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of boost radiotherapy in early invasive ductal breast cancer with ductal carcinoma in situ component under negative surgical margins.
    Shimizu N; Myojin M; Tamura M; Nishiyama N; Yamashiro K; Yuyama Y; Okazaki Y; Suzuki Y; Takahashi M
    J Radiat Res; 2022 Jan; 63(1):80-87. PubMed ID: 34718690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excision alone for small size ductal carcinoma in situ of the breast.
    Kim H; Noh JM; Choi DH; Lee J; Nam SJ; Lee JE; Park W; Huh SJ
    Breast; 2014 Oct; 23(5):586-90. PubMed ID: 24969239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Rudloff U; Brogi E; Brockway JP; Goldberg JI; Cranor M; Wynveen CA; Nehhozina T; Reiner AS; Patil S; Van Zee KJ
    Cancer; 2009 Mar; 115(6):1203-14. PubMed ID: 19170233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
    Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
    Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network meta-analysis of margin threshold for women with ductal carcinoma in situ.
    Wang SY; Chu H; Shamliyan T; Jalal H; Kuntz KM; Kane RL; Virnig BA
    J Natl Cancer Inst; 2012 Apr; 104(7):507-16. PubMed ID: 22440677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning.
    Yi M; Buchholz TA; Meric-Bernstam F; Bedrosian I; Hwang RF; Ross MI; Kuerer HM; Luo S; Gonzalez-Angulo AM; Buzdar AU; Symmans WF; Feig BW; Lucci A; Huang EH; Hunt KK
    Ann Surg; 2011 Mar; 253(3):572-9. PubMed ID: 21209588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.
    Schmitz RSJM; van den Belt-Dusebout AW; Clements K; Ren Y; Cresta C; Timbres J; Liu YH; Byng D; Lynch T; Menegaz BA; Collyar D; Hyslop T; Thomas S; Love JK; Schaapveld M; Bhattacharjee P; Ryser MD; Sawyer E; Hwang ES; Thompson A; Wesseling J; Lips EH; Schmidt MK;
    BMJ; 2023 Oct; 383():e076022. PubMed ID: 37903527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.